GLP-1 and Dual/Triple Agonist Peptide Drugs Show Promise for Fatty Liver Disease | Research

The takeaway

GLP-1 receptor agonists and novel dual/triple incretin agonists (targeting GLP-1/GIP/glucagon receptors) show significant improvements in weight, insulin resistance, and liver parameters for metabolic fatty liver disease.

Single → dual → triple
Evolution from GLP-1-only drugs to multi-receptor agonists targeting GLP-1, GIP, and glucagon pathways for better liver outcomes

What the researchers found

GLP-1RAs improve MAFLD/MASH through glucose and lipid metabolism regulation, with dual (GLP-1/GIP, GLP-1/GCR) and triple incretin agonists showing additional benefits in phase II trials for weight, insulin resistance, and liver parameters.

Why it matters

MAFLD affects about 30% of the global population and can progress to cirrhosis and liver cancer. Incretin-based peptide drugs offer the first promising pharmaceutical treatment approach.

How the study worked

Narrative review of mechanisms and clinical evidence for incretin-based therapies in MAFLD/MASH, covering GLP-1RAs, dual agonists, and triple agonists.

What this study cannot tell us

Most data from phase II trials with relatively short follow-up. Whether liver histology improvements prevent cirrhosis long-term is unknown. Patient selection criteria vary across trials.

How to read the evidence

Review of mostly phase II RCT data with strong mechanistic rationale. Phase III confirmatory trials ongoing.

When this study was published

Published in 2025, covering the latest clinical trial landscape for incretin-based liver therapies.

The bigger picture

The evolution from single-target GLP-1 drugs to multi-target incretin agonists represents a broader trend toward peptide drugs that address multiple metabolic pathways simultaneously.

Questions still open

Will phase III trials confirm the liver benefits seen in phase II?
Which multi-target agonist combination (GLP-1/GIP vs GLP-1/glucagon vs triple) is optimal for MAFLD?
Should GLP-1 drugs be standard care for diabetic patients with fatty liver?

Common questions

Can GLP-1 drugs treat fatty liver disease?

Growing evidence shows GLP-1 drugs improve fatty liver by reducing weight, improving insulin resistance, and directly affecting liver fat metabolism. Newer dual and triple agonist peptides may be even more effective.

What is MAFLD and why is it hard to treat?

MAFLD (metabolic-associated fatty liver disease) is fat buildup in the liver driven by metabolic dysfunction. It affects about 30% of people globally and can lead to cirrhosis and liver cancer. Until recently, there were no approved drug treatments.

Read the original research

Advances in Incretin-Based Therapies for MAFLD: Mechanisms and Clinical Evidence.

Clinical pharmacology and therapeutics, 119(2), 336-349

View on PubMed ↗Publisher’s paper ↗

Citation

Dong, Wenqi; Zhang, Haiming; Mu, Shaowei; Shi, Shuyi; Zhang, Junli; Xu, Keshu. (2026). Advances in Incretin-Based Therapies for MAFLD: Mechanisms and Clinical Evidence.. Clinical pharmacology and therapeutics, 119(2), 336-349. https://doi.org/10.1002/cpt.70131